Recruitment of 690 patients with chronic migraine and episodic migraine in the United States, Canada and Australia
Daewoong Pharmaceutical announced on March 9 that AEON Biopharma, its partner in botulinum toxin treatment business, has started recruiting patients after receiving approval from the U.S. Food and Drug Administration (FDA) for the second phase of clinical treatment for migraine.
AEON BioPharma will conduct clinical trials on 690 adult patients who suffer from migraine more than six days a month in the United States, Canada and Australia.
The clinician aims to simultaneously ensure preventive treatment for chronic migraines that experience headaches more than 15 days a month and episodic migraines that show symptoms less than 15 days a month.
Migraine is one of the most common diseases in the world, with about 40 million people in the United States and about 1 billion people worldwide. The number of chronic migraine patients is estimated at 2.2 million in the United States.
AEON Biopharma is an exclusive partner in the United States, Europe, and Canada that has the right to permit, import, and sell botulinum toxin formulations of Daewoong Pharmaceutical for treatment purposes.
Starting with Cervical Dystonia, which was approved for Phase 2 clinical trial last year, the company plans to start clinical trials on treatment adaptations and continue to acquire additional adaptations for treatment of chronic diseases.
Park Sung-soo, head of Daewoong Pharmaceutical's Nabota Business Division, said, "The botulinum toxin treatment market accounts for more than twice the beauty market and is highly likely to grow. It is a representative project that Daewoong Pharmaceutical has prepared to the full extent."
